Insider Buying: Coya Therapeutics, Inc. (NASDAQ:COYA) CFO Buys $12,942.00 in Stock

Coya Therapeutics, Inc. (NASDAQ:COYA) CFO David S. Snyder acquired 1,800 shares of Coya Therapeutics stock in a transaction dated Thursday, November 14th. The shares were bought at an average price of $7.19 per share, for a total transaction of $12,942.00. Following the transaction, the chief financial officer now owns 8,800 shares of the company’s stock, valued at approximately $63,272. The trade was a 25.71 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Coya Therapeutics Trading Down 7.2 %

NASDAQ COYA opened at $6.32 on Friday. The stock has a 50 day moving average price of $7.12 and a 200-day moving average price of $6.99. Coya Therapeutics, Inc. has a one year low of $4.75 and a one year high of $10.69.

Coya Therapeutics (NASDAQ:COYA) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.41) by $0.15. On average, sell-side analysts predict that Coya Therapeutics, Inc. will post -1.15 earnings per share for the current fiscal year.

Analysts Set New Price Targets

COYA has been the subject of several research analyst reports. Chardan Capital reaffirmed a “buy” rating and set a $14.00 target price on shares of Coya Therapeutics in a research note on Thursday, November 7th. HC Wainwright restated a “buy” rating and set a $18.00 price objective on shares of Coya Therapeutics in a research report on Monday, November 11th.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Geode Capital Management LLC increased its stake in Coya Therapeutics by 3.3% during the third quarter. Geode Capital Management LLC now owns 142,309 shares of the company’s stock worth $918,000 after acquiring an additional 4,485 shares during the last quarter. GHP Investment Advisors Inc. purchased a new position in shares of Coya Therapeutics in the 3rd quarter worth approximately $169,000. Renaissance Technologies LLC bought a new position in shares of Coya Therapeutics during the 2nd quarter valued at approximately $101,000. Gilbert & Cook Inc. purchased a new stake in Coya Therapeutics during the 2nd quarter valued at $61,000. Finally, Vanguard Group Inc. lifted its position in Coya Therapeutics by 772.3% in the first quarter. Vanguard Group Inc. now owns 847,490 shares of the company’s stock worth $8,407,000 after buying an additional 750,338 shares during the last quarter. Institutional investors own 39.75% of the company’s stock.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.